Spots Global Cancer Trial Database for plasma cell myeloma
Every month we try and update this database with for plasma cell myeloma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma | NCT05288062 | Plasma Cell Mye... Recurrent Plasm... Refractory Plas... Smoldering Plas... | Bone Marrow Bio... Dexamethasone Lenalidomide Pomalidomide | 18 Years - | Mayo Clinic | |
| Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma | NCT02492750 | Indolent Plasma... Plasma Cell Mye... Smoldering Plas... | Anakinra Dexamethasone Laboratory Biom... Lenalidomide Placebo | 18 Years - | Mayo Clinic | |
| Daratumumab in Treating Patients With Multiple Myeloma | NCT02944565 | Plasma Cell Mye... | Daratumumab | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies | NCT03272633 | Acute Lymphobla... Acute Myeloid L... Hematopoietic C... JAK2 Gene Mutat... Loss of Chromos... Mantle Cell Lym... Minimal Residua... Myelodysplastic... Non-Hodgkin Lym... Plasma Cell Mye... RAS Family Gene... Recurrent Diffu... Recurrent Hemat... Recurrent Matur... Refractory Diff... Refractory Matu... Therapy-Related... Therapy-Related... TP53 Gene Mutat... | Allogeneic Hema... Irradiated Allo... | 18 Years - | Rutgers, The State University of New Jersey | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | NCT04309084 | Multiple Myelom... Neoplasm, Plasm... Neoplasms by Hi... Neoplasms Hemostatic Diso... Vascular Diseas... Cardiovascular ... Paraproteinemia... Blood Protein D... Hematologic Dis... Hemorrhagic Dis... Lymphoprolifera... Immunoprolifera... Immune System D... Antineoplastic ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... Physiological E... | CYNK-001 | 18 Years - 75 Years | Celularity Incorporated | |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | NCT05400122 | Colorectal Canc... Hematologic Mal... Rectum Cancer Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Chronic Myeloid... Chronic Lymphoc... Hodgkin Lymphom... Non Hodgkin Lym... Myeloproliferat... Plasma Cell Mye... | Vactosertib Fludarabine Pho... Cyclophosphamid... IL-2 Natural Killer ... | 18 Years - | Case Comprehensive Cancer Center | |
| Exercise Prescription for the Improvement of Quality of Life in Elderly Patients With Multiple Myeloma | NCT04100044 | Plasma Cell Mye... | Exercise Counse... Exercise Interv... Questionnaire a... Quality-of-Life... | 65 Years - | Thomas Jefferson University | |
| International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab | NCT05669989 | Plasma Cell Mye... | Isatuximab IV (... Cemiplimab (SAR... Dexamethasone Lenalidomide Pomalidomide Isatuximab SC (... | 18 Years - | Sanofi | |
| Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients | NCT03275285 | Plasma Cell Mye... | isatuximab SAR6... carfilzomib dexamethasone | 18 Years - | Sanofi | |
| A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | NCT04458831 | Plasma Cell Mye... | isatuximab SAR6... Pomalidomide Dexamethasone Carfilzomib | 18 Years - | Sanofi | |
| Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial | NCT05497804 | ISS Stage III P... Plasma Cell Mye... | Bone Marrow Asp... Carfilzomib Computed Tomogr... Daratumumab Dexamethasone Lenalidomide Magnetic Resona... Positron Emissi... | 18 Years - 80 Years | Mayo Clinic | |
| 90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT01503242 | Plasma Cell Mye... Refractory Plas... | Allogeneic Hema... Cyclosporine Fludarabine Pho... Mycophenolate M... Peripheral Bloo... Total-Body Irra... Yttrium Y 90 An... | 18 Years - 65 Years | Fred Hutchinson Cancer Center | |
| Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation | NCT05005299 | Leukemia, Myelo... Leukemia, Lymph... Leukemia, Lymph... Myelodysplastic... Non-hodgkin Lym... Plasma Cell Mye... | Venetoclax Fludarabine Cyclophosphamid... | 18 Years - 75 Years | Melbourne Health | |
| Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | NCT05031897 | Acute Lymphobla... Acute Myeloid L... Aplastic Anemia Chronic Lymphoc... Chronic Myelomo... Essential Throm... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloid Leukemi... Myeloid Neoplas... Non-Hodgkin Lym... Plasma Cell Mye... Polycythemia Ve... Small Lymphocyt... | Hematopoietic C... Mycophenolate M... Tacrolimus Cyclophosphamid... Total-Body Irra... Donor Lymphocyt... Fludarabine Melphalan | 18 Years - | Thomas Jefferson University | |
| Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients | NCT04065789 | Myeloma Multipl... Myeloma, Plasma... Myeloma-Multipl... Plasma Cell Mye... | Carfilzomib Daratumumab Lenalidomide Dexamethasone | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma | NCT04579523 | Plasma Cell Mye... Recurrent Plasm... Refractory Plas... | Allogeneic Hema... Astatine At 211... Cyclophosphamid... Fludarabine Pho... Total-Body Irra... | 18 Years - 70 Years | Fred Hutchinson Cancer Center | |
| Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | NCT02566304 | Acute Myeloid L... Acute Myeloid L... Aplastic Anemia Chronic Myelomo... Hodgkin Lymphom... Indolent Non-Ho... Malignant Neopl... Myelodysplastic... Myeloproliferat... Plasma Cell Mye... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto... | Fludarabine Total-Body Irra... T Cell-Depleted... Cyclophosphamid... Peripheral Bloo... Allogeneic Hema... Tacrolimus Mycophenolate m... Laboratory Biom... | 18 Years - | Thomas Jefferson University | |
| Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT01251575 | Adult Acute Lym... Adult Acute Mye... Adult Diffuse L... Adult Myelodysp... Adult Non-Hodgk... Aggressive Non-... Childhood Acute... Childhood Acute... Childhood Diffu... Childhood Myelo... Childhood Non-H... Chronic Lymphoc... Chronic Lymphoc... Chronic Phase C... Hematopoietic a... Mantle Cell Lym... Plasma Cell Mye... Prolymphocytic ... Recurrent Chron... Refractory Chro... T-Cell Prolymph... Waldenstrom Mac... Recurrent Diffu... Recurrent Hodgk... | Allogeneic Hema... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Sirolimus Total-Body Irra... | - | Fred Hutchinson Cancer Center | |
| Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma | NCT05208307 | Plasma Cell Mye... | Belantamab Mafo... Dexamethasone Pomalidomide | 18 Years - | Emory University | |
| Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial | NCT04566328 | Plasma Cell Mye... RISS Stage I Pl... RISS Stage II P... | Bortezomib Daratumumab and... Dexamethasone Lenalidomide Quality-of-Life... | 18 Years - | Eastern Cooperative Oncology Group | |
| Collection of Transplant Stem Cells for Plasma Cell Myeloma | NCT01547806 | Plasma Cell Mye... Multiple Myelom... | Filgrastim Plerixafor Apheresis | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Dalteparin in Preventing DVT in Participants With Cancer | NCT00525057 | Bone Sarcoma Femur Fracture Lymphoma Metastatic Neop... Pathologic Frac... Plasma Cell Mye... Soft Tissue Sar... | Dalteparin | 30 Years - | M.D. Anderson Cancer Center | |
| Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT02353572 | Plasma Cell Mye... Plasmacytosis Recurrent Plasm... Smoldering Plas... | Melphalan Bortezomib Dexamethasone Autologous Tran... | 18 Years - 70 Years | University of Colorado, Denver | |
| Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study | NCT05972577 | Acute Lymphobla... Acute Myeloid L... Aplastic Anemia Chronic Lymphoc... Chronic Myeloge... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym... Plasma Cell Mye... | Health Promotio... Medical Device ... Quality-of-Life... Questionnaire A... | 60 Years - | Ohio State University Comprehensive Cancer Center | |
| Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients | NCT04065789 | Myeloma Multipl... Myeloma, Plasma... Myeloma-Multipl... Plasma Cell Mye... | Carfilzomib Daratumumab Lenalidomide Dexamethasone | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma | NCT03311828 | Recurrent Plasm... Plasma Cell Mye... Secondary Amylo... | Daratumumab Imaging Agent Positron Emissi... Pharmacological... | 18 Years - | City of Hope Medical Center | |
| Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study | NCT05053100 | Acute Leukemia Deep Vein Throm... Hematopoietic a... Hodgkin Lymphom... Myeloproliferat... Non-Hodgkin Lym... Plasma Cell Mye... Thrombocytopeni... | Biospecimen Col... Electronic Heal... | 18 Years - | Mayo Clinic | |
| Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | NCT01251575 | Adult Acute Lym... Adult Acute Mye... Adult Diffuse L... Adult Myelodysp... Adult Non-Hodgk... Aggressive Non-... Childhood Acute... Childhood Acute... Childhood Diffu... Childhood Myelo... Childhood Non-H... Chronic Lymphoc... Chronic Lymphoc... Chronic Phase C... Hematopoietic a... Mantle Cell Lym... Plasma Cell Mye... Prolymphocytic ... Recurrent Chron... Refractory Chro... T-Cell Prolymph... Waldenstrom Mac... Recurrent Diffu... Recurrent Hodgk... | Allogeneic Hema... Cyclosporine Fludarabine Pho... Laboratory Biom... Mycophenolate M... Peripheral Bloo... Sirolimus Total-Body Irra... | - | Fred Hutchinson Cancer Center | |
| Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy | NCT05204160 | Plasma Cell Mye... | Pembrolizumab | 18 Years - | Emory University | |
| Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma | NCT04466475 | Plasma Cell Mye... | Astatine At 211... Melphalan Peripheral Bloo... | 18 Years - | Fred Hutchinson Cancer Center | |
| S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT01055301 | Multiple Myelom... Plasma Cell Mye... | bortezomib cisplatin cyclophosphamid... dexamethasone doxorubicin hyd... etoposide lenalidomide melphalan thalidomide gene expression... microarray anal... laboratory biom... autologous-auto... | 18 Years - 65 Years | SWOG Cancer Research Network | |
| Telehealth Exercise Intervention to Improve Physical Function and Frailty in Multiple Myeloma Survivors | NCT05142371 | Plasma Cell Mye... | Best Practice Exercise Interv... Quality-of-Life... Questionnaire A... | 18 Years - | City of Hope Medical Center | |
| Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma | NCT03870451 | Chemotherapy-in... Plasma Cell Mye... | VascuTherm5 vas... | 18 Years - | Wake Forest University Health Sciences | |
| Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies | NCT01919619 | B-Cell Non-Hodg... Hematopoietic a... Leukemia Lymphoma Plasma Cell Mye... T-Cell Non-Hodg... | Ipilimumab Lenalidomide | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma | NCT04466475 | Plasma Cell Mye... | Astatine At 211... Melphalan Peripheral Bloo... | 18 Years - | Fred Hutchinson Cancer Center | |
| Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma | NCT02492750 | Indolent Plasma... Plasma Cell Mye... Smoldering Plas... | Anakinra Dexamethasone Laboratory Biom... Lenalidomide Placebo | 18 Years - | Mayo Clinic | |
| First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma | NCT04000282 | Plasma Cell Mye... | SAR442085 | 18 Years - | Sanofi | |
| Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers | NCT01240525 | Graft Versus Ho... Leukemia Lymphoma Myeloma Myelodysplastic... | CD4 DLI No DLI | 18 Years - 69 Years | University College, London | |
| SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients | NCT02283775 | Plasma Cell Mye... | Isatuximab SAR6... Pomalidomide Dexamethasone | 18 Years - | Sanofi | |
| Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT01729091 | Plasma Cell Leu... Plasma Cell Mye... | Autologous Hema... Elotuzumab Laboratory Biom... Lenalidomide Melphalan Natural Killer ... Umbilical Cord ... | 18 Years - 75 Years | M.D. Anderson Cancer Center | |
| Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT02353572 | Plasma Cell Mye... Plasmacytosis Recurrent Plasm... Smoldering Plas... | Melphalan Bortezomib Dexamethasone Autologous Tran... | 18 Years - 70 Years | University of Colorado, Denver | |
| Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial | NCT04566328 | Plasma Cell Mye... RISS Stage I Pl... RISS Stage II P... | Bortezomib Daratumumab and... Dexamethasone Lenalidomide Quality-of-Life... | 18 Years - | Eastern Cooperative Oncology Group | |
| S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT01055301 | Multiple Myelom... Plasma Cell Mye... | bortezomib cisplatin cyclophosphamid... dexamethasone doxorubicin hyd... etoposide lenalidomide melphalan thalidomide gene expression... microarray anal... laboratory biom... autologous-auto... | 18 Years - 65 Years | SWOG Cancer Research Network | |
| Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma | NCT03477539 | Plasma Cell Mye... | Autologous Hema... Daratumumab Lenalidomide | 18 Years - | Mayo Clinic | |
| Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma | NCT03311828 | Recurrent Plasm... Plasma Cell Mye... Secondary Amylo... | Daratumumab Imaging Agent Positron Emissi... Pharmacological... | 18 Years - | City of Hope Medical Center | |
| Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization | NCT04211259 | Plasma Cell Mye... | Loratadine Placebo Questionnaire A... | 18 Years - | Rutgers, The State University of New Jersey | |
| Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma | NCT03119883 | Monoclonal Gamm... Plasma Cell Mye... | 5-Carbon C 13-l... Biospecimen Col... Biospecimen Col... Uniformly-label... | 18 Years - | Mayo Clinic | |
| Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients | NCT03194867 | Plasma Cell Mye... | Isatuximab SAR6... Cemiplimab REGN... | 18 Years - | Sanofi | |
| S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT01055301 | Multiple Myelom... Plasma Cell Mye... | bortezomib cisplatin cyclophosphamid... dexamethasone doxorubicin hyd... etoposide lenalidomide melphalan thalidomide gene expression... microarray anal... laboratory biom... autologous-auto... | 18 Years - 65 Years | SWOG Cancer Research Network | |
| Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma | NCT03756896 | Plasma Cell Mye... | Carfilzomib Dexamethasone Pomalidomide | 18 Years - | Emory University | |
| Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant | NCT03319667 | Plasma Cell Mye... | Isatuximab SAR6... Bortezomib Lenalidomide Dexamethasone | 18 Years - 80 Years | Sanofi | |
| Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation | NCT05005299 | Leukemia, Myelo... Leukemia, Lymph... Leukemia, Lymph... Myelodysplastic... Non-hodgkin Lym... Plasma Cell Mye... | Venetoclax Fludarabine Cyclophosphamid... | 18 Years - 75 Years | Melbourne Health | |
| Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant | NCT02880228 | Plasma Cell Mye... | Dexamethasone Laboratory Biom... Lenalidomide Pembrolizumab | 18 Years - | Mayo Clinic | |
| Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery | NCT02955043 | Hodgkin Lymphom... Non-Hodgkin Lym... Plasma Cell Mye... Lymphoid Leukem... Myeloid Leukemi... Myelodysplastic... Multiple Myelom... | Behavioral tech... | 18 Years - 74 Years | University of Wisconsin, Madison | |
| Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy | NCT03078452 | Plasma Cell Mye... | Power drill Jamshidi needle | - | Emory University | |
| Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL | NCT05153330 | Acute Myeloid L... Acute Lymphobla... Acute Mixed-Phe... Cancer Refractory Progression Diffuse Large B... Multiple Myelom... Lymphoma Lymphoma, Non-H... Myeloma, Plasma... Myelomatosis Plasma Cell Mye... Chronic Lymphoc... Small Lymphocyt... | BMF-219 | 18 Years - | Biomea Fusion Inc. | |
| Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma | NCT03870451 | Chemotherapy-in... Plasma Cell Mye... | VascuTherm5 vas... | 18 Years - | Wake Forest University Health Sciences | |
| Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma | NCT04892264 | Plasma Cell Mye... Recurrent Plasm... Refractory Plas... | Belantamab Mafo... Daratumumab Dexamethasone Lenalidomide Quality-of-Life... Biospecimen Col... Skeletal Survey... Low Dose Comput... Bone Marrow Asp... Bone Marrow Bio... | 18 Years - | Mayo Clinic | |
| Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | NCT05400122 | Colorectal Canc... Hematologic Mal... Rectum Cancer Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Chronic Myeloid... Chronic Lymphoc... Hodgkin Lymphom... Non Hodgkin Lym... Myeloproliferat... Plasma Cell Mye... | Vactosertib Fludarabine Pho... Cyclophosphamid... IL-2 Natural Killer ... | 18 Years - | Case Comprehensive Cancer Center | |
| Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients | NCT03194867 | Plasma Cell Mye... | Isatuximab SAR6... Cemiplimab REGN... | 18 Years - | Sanofi | |
| Chaplain-Delivered Compassion Meditation to Improve Quality of Life in Patients Receiving a Stem Cell Transplant | NCT05274763 | Lymphoma Plasma Cell Mye... | Quality-of-Life... Questionnaire A... Spiritual Thera... | 18 Years - | Emory University | |
| Dalteparin in Preventing DVT in Participants With Cancer | NCT00525057 | Bone Sarcoma Femur Fracture Lymphoma Metastatic Neop... Pathologic Frac... Plasma Cell Mye... Soft Tissue Sar... | Dalteparin | 30 Years - | M.D. Anderson Cancer Center | |
| Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma | NCT03858205 | Bone Pain Metastatic Mali... Plasma Cell Mye... | Quality-of-Life... Questionnaire A... Radiation Thera... | 18 Years - | University of Southern California | |
| Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | NCT02566304 | Acute Myeloid L... Acute Myeloid L... Aplastic Anemia Chronic Myelomo... Hodgkin Lymphom... Indolent Non-Ho... Malignant Neopl... Myelodysplastic... Myeloproliferat... Plasma Cell Mye... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto... | Fludarabine Total-Body Irra... T Cell-Depleted... Cyclophosphamid... Peripheral Bloo... Allogeneic Hema... Tacrolimus Mycophenolate m... Laboratory Biom... | 18 Years - | Thomas Jefferson University | |
| Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT02619682 | Plasma Cell Mye... Transplant-Rela... | Ixazomib Citrat... Laboratory Biom... Lenalidomide | 18 Years - | Fred Hutchinson Cancer Center | |
| Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma | NCT02492750 | Indolent Plasma... Plasma Cell Mye... Smoldering Plas... | Anakinra Dexamethasone Laboratory Biom... Lenalidomide Placebo | 18 Years - | Mayo Clinic | |
| Home Based Daratumumab Administration for Patients With Multiple Myeloma | NCT05511428 | Plasma Cell Mye... | Daratumumab and... Questionnaire A... Quality-of-Life... Interview | 18 Years - | Thomas Jefferson University | |
| Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure | NCT04352205 | Plasma Cell Mye... Renal Failure | Bortezomib Daratumumab Dexamethasone Lenalidomide Thalidomide | 18 Years - | Emory University | |
| S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis | NCT00064337 | Multiple Myelom... Plasma Cell Mye... | filgrastim cyclophosphamid... dexamethasone melphalan thalidomide peripheral bloo... | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | NCT02890758 | Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Chronic Myeloid... Chronic Lymphoc... Non Hodgkin Lym... Hodgkin Lymphom... Myeloproliferat... Plasma Cell Mye... Colon Carcinoma Adenocarcinoma ... Soft Tissue Sar... Ewing's Sarcoma Rhabdomyosarcom... | Natural Killer ... ALT803 | 18 Years - | Case Comprehensive Cancer Center | |
| Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | NCT03192397 | Acute Myeloid L... Adult Acute Lym... Chronic Myeloge... Chronic Myelomo... Graft Versus Ho... Hodgkin Lymphom... Minimal Residua... Myelodysplastic... Myeloproliferat... Non-Hodgkin Lym... Plasma Cell Mye... Severe Aplastic... Waldenstrom Mac... | Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Melphalan Hydro... Mycophenolate M... Sirolimus Total-Body Irra... | 18 Years - | Roswell Park Cancer Institute | |
| Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT01718743 | Hematopoietic C... Plasma Cell Mye... | Ixazomib Citrat... Lenalidomide Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| Exercise Prescription for the Improvement of Quality of Life in Elderly Patients With Multiple Myeloma | NCT04100044 | Plasma Cell Mye... | Exercise Counse... Exercise Interv... Questionnaire a... Quality-of-Life... | 65 Years - | Thomas Jefferson University | |
| Assessment of Financial Difficulty in Participants With Chronic Lymphocytic Leukemia and Multiple Myeloma | NCT03870633 | Chronic Lymphoc... Plasma Cell Mye... | Medical Chart R... Interview Questionnaire Quality-of-Life... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies | NCT03272633 | Acute Lymphobla... Acute Myeloid L... Hematopoietic C... JAK2 Gene Mutat... Loss of Chromos... Mantle Cell Lym... Minimal Residua... Myelodysplastic... Non-Hodgkin Lym... Plasma Cell Mye... RAS Family Gene... Recurrent Diffu... Recurrent Hemat... Recurrent Matur... Refractory Diff... Refractory Matu... Therapy-Related... Therapy-Related... TP53 Gene Mutat... | Allogeneic Hema... Irradiated Allo... | 18 Years - | Rutgers, The State University of New Jersey | |
| Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant | NCT02389517 | Plasma Cell Mye... Residual Diseas... | Ixazomib Citrat... Lenalidomide Dexamethasone | 18 Years - | University of Chicago | |
| SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer | NCT04977024 | COVID-19 Infect... Hematopoietic a... Leukemia Lymphoma Plasma Cell Mye... | COVID-19 Vaccin... Diagnostic Labo... Synthetic MVA-b... | 18 Years - | GeoVax, Inc. | |
| A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma | NCT00431340 | Multiple Myelom... | PXD101 | 18 Years - | Valerio Therapeutics | |
| Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT02353572 | Plasma Cell Mye... Plasmacytosis Recurrent Plasm... Smoldering Plas... | Melphalan Bortezomib Dexamethasone Autologous Tran... | 18 Years - 70 Years | University of Colorado, Denver | |
| Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers | NCT01240525 | Graft Versus Ho... Leukemia Lymphoma Myeloma Myelodysplastic... | CD4 DLI No DLI | 18 Years - 69 Years | University College, London |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
